COMMUNIQUÉS West-GlobeNewswire

Teneobio Announces a Strategic Alliance with TESARO to Develop the Next Generation of Immuno-Oncology, Multispecific Antibodies
08/01/2018
MENLO PARK, Calif., Jan. 08, 2018 (GLOBE NEWSWIRE) -- Teneobio, Inc., a next generation multi-specific antibody therapeutics company announced today the initiation of a research collaboration and licensing agreement [...]
AMAG Pharmaceuticals Announces Preliminary 2017 Financial Results and Provides 2018 Guidance
08/01/2018
WALTHAM, Mass., Jan. 08, 2018 (GLOBE NEWSWIRE) -- AMAG Pharmaceuticals, Inc. (NASDAQ: AMAG ) today provided a business update, including preliminary unaudited fourth quarter and full year 2017 financial results and 2018 [...]
Athenex Announces Chinese FDA Allowance of Investigational New Drug Application of Oraxol to Begin Clinical Trials
08/01/2018
BUFFALO, N.Y., Jan. 08, 2018 (GLOBE NEWSWIRE) -- Athenex, Inc. (Nasdaq: ATNX ), a global biopharmaceutical company dedicated to the discovery, development and commercialization of novel therapies for the treatment of [...]
REGENXBIO and AveXis Announce Expansion of Relationship through Amended License Agreement for the Development and Commercialization of Treatments for Spinal Muscular Atrophy
08/01/2018
AveXis acquires exclusive rights to entire NAV Technology Platform for the development of treatments for SMA Amended agreement permits assignment by AveXis upon a change of control without REGENXBIO’s consent REGENXBIO [...]
Sientra Announces Preliminary Unaudited Fourth Quarter 2017 Revenue
08/01/2018
Board Member Keith Sullivan Appointed Interim General Manager of miraDry Miramar Labs Officially Named miraDry, a Sientra Subsidiary Universal Shelf Registration Filed on Form S-3 SANTA BARBARA, Calif., Jan. 08, 2018 ( [...]
Ascendis Pharma Provides Update on Rare Disease Endocrinology Pipeline and Presents Initial Phase 1 Data for TransCon PTH
08/01/2018
COPENHAGEN, Denmark, Jan. 08, 2018 (GLOBE NEWSWIRE) -- Ascendis Pharma A/S (Nasdaq: ASND ), a biopharmaceutical company that utilizes its innovative TransCon technology to address significant unmet medical needs in rare [...]
UroGen Pharma Appoints Former Kite Pharma Executive Christine Cassiano as Corporate Affairs Officer
08/01/2018
Kate Bechtold, Also Formerly of Kite Pharma, to Join the Expanded Communications Team as Director of Corporate Communications & Investor Relations RA’ANANA, Israel, and NEW YORK, Jan. 08, 2018 (GLOBE NEWSWIRE) -- [...]
SeaSpine Announces Preliminary Results for Fourth Quarter and Full-Year 2017
08/01/2018
CARLSBAD, Calif., Jan. 08, 2018 (GLOBE NEWSWIRE) -- SeaSpine Holdings Corporation (NASDAQ: SPNE ), a global medical technology company focused on surgical solutions for the treatment of spinal disorders, announced today [...]
BIOSIG TECHNOLOGIES COMPLETES PRIVATE PLACEMENT
08/01/2018
Santa Monica, CA, Jan. 08, 2018 (GLOBE NEWSWIRE) -- BioSig Technologies, Inc. (OTCQB: BSGM), a medical device company developing a proprietary biomedical signal processing platform designed to address an unmet [...]
Inovio Receives Milestone Payment from MedImmune as MEDI0457 and Checkpoint Inhibitor Combination Trial in Head and Neck Squamous Cell Cancer Advances to Phase 2
08/01/2018
PLYMOUTH MEETING, Pa., Jan. 08, 2018 (GLOBE NEWSWIRE) -- Inovio Pharmaceuticals, Inc. (NASDAQ: INO ) announced today it has received a milestone payment from MedImmune as MEDI0457 (formerly called INO-3112 which [...]
XOMA Strengthens Leadership Team with Appointments of Chief Business Officer and General Counsel
08/01/2018
EMERYVILLE, Calif., Jan. 08, 2018 (GLOBE NEWSWIRE) -- XOMA Corporation (Nasdaq: XOMA ), a pioneer in the discovery, development and licensing of therapeutic antibodies, today announced the appointments of Dee Datta, Ph. [...]
IRIDEX Announces Preliminary Operational and Financial Results for 2017 Fourth Quarter and Full Year
08/01/2018
MOUNTAIN VIEW, Calif., Jan. 08, 2018 (GLOBE NEWSWIRE) -- IRIDEX Corporation (Nasdaq: IRIX ) today provided preliminary operational and financial results for the fourth quarter and full year ended December 30, 2017. [...]
Kamada Announces Interim Results from Phase 2 Clinical Trial of Intravenous Alpha-1 Antitrypsin Treatment for Prevention of Lung Transplant Rejection
08/01/2018
Kamada’s IV AAT Demonstrated Favorable Safety and Tolerability Profile in 10 Patients During First Six Months of Treatment, Consistent with Previously Observed Results in Other Indications Next Interim Report Expected [...]
Microbot Medical Enters into Agreement to Acquire Novel Technology to Enhance Existing Technology Platforms and Strengthen Patent Portfolio
08/01/2018
HINGHAM, Mass., Jan. 08, 2018 (GLOBE NEWSWIRE) -- Microbot Medical Inc. (NASDAQ CM:MBOT), a medical device company specializing in the design and development of transformational micro-robotic medical technologies, today [...]
Oncolix Initiates Patient Recruitment of Second Cohort of Prolanta™ Phase 1 Trial in Advanced Ovarian Cancer
08/01/2018
HOUSTON, Jan. 08, 2018 (GLOBE NEWSWIRE) -- Oncolix, Inc., (OTCQB:ONCX) announced today that the Company’s clinical site investigator has initiated patient recruitment for the second dosing group for the Prolanta™ Phase [...]
Aclaris Therapeutics’ A-101 45% Topical Solution Meets Primary and All Secondary Endpoints in Two Phase 2 Clinical Trials for Common Warts
08/01/2018
Highly statistically significant results on all primary and secondary endpoints Statistical significance seen as early as day 28, after 4 weeks of treatment in WART-203 If approved, A-101 45% would be the first FDA [...]
NeuroMetrix Reports Preliminary 2017 Financial Highlights
08/01/2018
WALTHAM, Mass., Jan. 08, 2018 (GLOBE NEWSWIRE) -- NeuroMetrix, Inc. (Nasdaq: NURO ) today reported preliminary financial highlights for the fourth quarter and for the full year 2017. GAAP revenue for the fourth quarter [...]
Inovalon Expects Fourth Quarter Revenue Growth of 18% to 20% and Adjusted EBITDA Growth of 78% Assuming the Midpoint, Consistent with Prior Guidance
08/01/2018
Company Issues Preliminary Fourth Quarter and Full Year 2017 Expectations In Conjunction with J.P. Morgan Healthcare Conference Participation Preliminary Fourth Quarter 2017 Expectations Fourth quarter revenue expected [...]
AxoGen, Inc. Preannounces Estimated Fourth Quarter and Full Year 2017 Revenue
08/01/2018
Q4 Revenue will be at least $16.5 million, representing 45% growth over prior year 2017 Revenue will be at least $60.0 million, representing 46% growth over prior year ALACHUA, Fla., Jan. 08, 2018 (GLOBE NEWSWIRE) -- [...]

Pages